Similarly, while our study proposes these hub genes as potential novel therapeutic targets, their detailed clinical implications, including potential interactions with existing T2D therapies such as SGLT2 inhibitors, remain to be elucidated and represent an important avenue for future translational research once their functional roles are more firmly established. Here, SLC5A2 is linked to type 2 diabetes mellitus.